Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Volunteer

Interventions

DRUG

MD-18

MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Trial Locations (1)

RECRUITING

Sheba Medical Center, Ramat Gan

All Listed Sponsors

lead

Cohen Global, Ltd.

INDUSTRY